Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trialJean Chastre, Tomas Hruby, Ricard Ferrer et al.|Critical Care|2022Cited by 93
635. Efficacy, Pharmacokinetics (PK), and Safety Profile of MEDI3902, an Anti-<i>Pseudomonas aeruginosa</i> Bispecific Human Monoclonal Antibody in Mechanically Ventilated Intensive Care Unit Patients; Results of the Phase 2 EVADE Study Conducted by the Public-Private COMBACTE-MAGNET Consortium in the Innovative Medicines Initiative (IMI) ProgramJean Chastre, Hasan S. Jafri, Bruno François et al.|Open Forum Infectious Diseases|2020Cited by 16